Why New US Investment Curbs Might Stall China’s Biotech Licensing Boom

Why New US Investment Curbs Might Stall China’s Biotech Licensing Boom

Western pharmaceutical giants have spent the last three years shopping in China like it's a clearance sale. They've poured billions of dollars into licensing deals for Chinese-developed cancer therapies, weight-loss drugs, and autoimmune treatments. Now, Washington is threatening to pull the plug on the capital pipeline that keeps those Chinese labs running.

If you've been watching the cross-border biotech space, you know the numbers are staggering. Chinese biotechs have gone from copycats to primary innovation engines for Big Pharma in less than a decade. Yet new US outbound investment restrictions—alongside the lingering shadow of the BIOSECURE Act—are forcing American venture capitalists and pharmaceutical executives to ask an uncomfortable question. Can China's biotech licensing surge survive if US dollars are legally barred from funding the underlying research?

The short answer is complicated. While licensing intellectual property isn't explicitly banned under current outbound investment rules, starving Chinese startups of early-stage US venture capital will inevitably dry up the pipeline of drugs available to license three or four years from now.

How China Became Big Pharma’s Favorite Drugstore

To understand why these investment curbs matter so much, you have to look at how the pharmaceutical business model has shifted. Major Western drugmakers are staring down a massive patent cliff between now and 2030. Blockbuster drugs are losing exclusivity, and internal R&D departments at companies like Merck, AstraZeneca, and Pfizer simply aren't moving fast enough to replace that lost revenue.

Enter China.

Over the past few years, Chinese biotech firms figured out how to run clinical trials faster and cheaper than almost anywhere else on earth. A phase 1 oncology trial in Shanghai or Suzhou can recruit patients in a fraction of the time it takes in Boston or San Francisco. Because domestic Chinese capital dried up after the 2021 market crash and strict pricing caps from China's National Reimbursement Drug List squeezed local profit margins, Chinese biotechs desperately needed cash.

Licensing their molecules to Western companies became their lifeline.

Instead of spending hundreds of millions of dollars trying to commercialize a drug in the US on their own, Chinese firms started selling the global rights (excluding China) to Western pharma giants for hefty upfront payments and milestone fees. According to industry data from DealForma and Stifel, out-licensing deals from China hit record highs in 2023 and 2024, accounting for roughly a quarter to a third of all large-cap pharma licensing volume.

Think about that. One in every three major external drug deals signed by Western pharma involved a molecule discovered in China.

What the New US Outbound Investment Curbs Actually Target

Here is where the geopolitical friction kicks in. The US Treasury Department's outbound investment security program—stemming from Executive Order 14105—originally focused on semiconductors, quantum computing, and artificial intelligence. But lawmakers in Washington have repeatedly pushed to expand these restrictions into biotechnology, viewing advanced biologics, genetic engineering, and AI-driven drug discovery as national security priorities.

Let's be clear about what these rules do and don't do right now.

  • Direct equity investments are in the crosshairs. US venture capital firms, private equity funds, and corporate venture arms face strict prohibitions or mandatory notification requirements when putting money into Chinese entities working on sensitive dual-use technologies.
  • Passive LP money is getting squeezed. Even if a US pension fund or university endowment isn't picking Chinese biotech stocks directly, Treasury rules restrict how US capital flows into foreign funds that invest in restricted Chinese sectors.
  • Asset licensing sits in a gray zone. Buying the rights to a specific drug molecule through an upfront licensing payment isn't technically an equity investment in a Chinese company. That distinction is what keeps deals moving today.

But you can't separate the fruit from the tree.

If US venture firms like Sequoia's former China arm (now HongShan, which still relies on global LPs), ORBIMED, or Flagship-style syndicates pull back from Series A and Series B rounds in China because of compliance headaches, who funds the next wave of Chinese drug discovery? Domestic Chinese venture capital is still sluggish, and state-backed funds tend to favor safe, late-stage manufacturing over risky, early-stage biology.

I've spoken with several cross-border biotech advisors over the past year, and they all point to the same structural flaw in the "licensing is safe" argument.

Big Pharma rarely buys an idea on a napkin. Companies like GSK, Novartis, and Roche want to see Phase 1 human clinical data before they hand over $100 million upfront. Getting a drug from a university lab bench through animal testing and into its first human trial costs anywhere from $15 million to $40 million.

Historically, US and global syndicate investors provided a huge chunk of that bridge capital. They brought more than just money—they brought FDA regulatory expertise, global clinical trial design standards, and introductions to Big Pharma business development teams.

Without US venture involvement:

  1. Early-stage Chinese biotechs struggle to raise the $30 million needed to generate Phase 1 data.
  2. Clinical trials designed solely for China's National Medical Products Administration (NMPA) often fail to meet the stricter demographic and regulatory standards required by the US FDA.
  3. Big Pharma becomes hesitant to license assets if the underlying clinical data package looks messy or lacks Western oversight.

It's a slow-motion bottleneck. You won't see licensing deals drop to zero tomorrow morning. The drugs being licensed right now were funded back in 2020 and 2021. The real impact of today's investment curbs will show up in 2028 and 2029, when Big Pharma goes looking for the next generation of antibody-drug conjugates (ADCs) and bispecific antibodies, only to find the cupboard half empty.

The NewCo Workaround and Why Washington Is Watching It

Biotech lawyers are creative people. Whenever Washington closes a door, someone in Boston or Shanghai tries to climb through a window.

Right now, the hottest trend in cross-border biotech is the "NewCo" model. Instead of a Western pharma company licensing a drug directly from a Chinese biotech—or a US VC investing directly into a Shanghai entity—they create a brand-new, Delaware-incorporated company based in the US.

Here is how the NewCo playbook works in practice. A Chinese biotech spins out the global rights to one of its promising drug candidates into this new US entity. In exchange, the Chinese company gets an upfront cash payment and a minority equity stake (usually under 20%) in the new American company. Meanwhile, a syndicate of US venture capitalists puts $50 million to $100 million directly into the Delaware NewCo, hires an American CEO, and runs global clinical trials out of Boston or San Francisco.

Everybody wins, right? The US VC gets to invest in an American company. The Chinese biotech gets non-dilutive cash to survive back home. And Big Pharma can eventually acquire the NewCo without touching a Chinese corporate entity.

Except Washington isn't stupid.

Congressional committees—particularly the House Select Committee on the Chinese Communist Party—have already flagged corporate spin-outs and IP transfer structures as potential loopholes. If Treasury updates its outbound investment definitions to capture joint ventures, IP spin-outs, or deals where a Chinese entity retains significant board influence or royalty streams, the NewCo model could hit a brick wall overnight.

What About the BIOSECURE Act Fallout

You can't talk about US investment curbs without mentioning the elephant in the room. The BIOSECURE Act, which restricts federal contracts with companies that rely on certain Chinese contract research and manufacturing organizations (like WuXi AppTec and WuXi Biologics), has already rattled the industry.

Even though BIOSECURE targets supply chains rather than venture capital, the psychological chill on investors is identical.

Imagine you're a partner at a US biotech venture fund. Your investment committee is looking at two deals. Deal A is a startup in Cambridge, Massachusetts, using an American contract manufacturer. Deal B is a NewCo licensing a molecule discovered in Suzhou, where the early toxicology studies were run by WuXi AppTec.

Even if Deal B has better science, the regulatory and reputational friction is exhausting. Your LPs are asking uncomfortable questions about geopolitical exposure. Your Big Pharma acquirers are demanding extra indemnities in case future legislation blacklists data generated by Chinese contractors.

When compliance costs and geopolitical risk premiums spike, capital naturally flows toward the path of least resistance.

How Smart Biotech Investors and Founders Are Adapting

If you're an investor, a business development executive, or a founder navigating this mess, waiting around for Washington and Beijing to kiss and make up is a terrible strategy. Geopolitical friction around biotechnology is bipartisan and permanent.

Here is what the sharpest operators in the space are doing right now to protect their pipelines:

  • Decoupling R&D data early. Cross-border startups are running discovery work in China to take advantage of lower costs, then immediately transferring cell lines and manufacturing processes to US or European CDMOs before IND-enabling toxicology studies begin. Clean data provenance is worth its weight in gold during Big Pharma due diligence.
  • Looking beyond China for value. Big Pharma business development teams are actively scouting South Korea, Japan, and Europe to diversify their external innovation pipelines. South Korean biotechs, in particular, have seen a noticeable uptick in ADC and platform licensing interest as Western buyers hedge against China risk.
  • Structuring clean, passive equity stakes. In NewCo transactions, lawyers are stripping Chinese parent companies of board seats, veto rights, and operational control. Keeping the Chinese entity strictly as a passive minority shareholder and licensor reduces the odds of triggering Treasury scrutiny or CFIUS reviews down the road.
  • Pricing in the geopolitical discount. Upfront payments for China-originated assets haven't disappeared, but buyers are pushing more value into backend clinical and commercial milestones. Nobody wants to risk $200 million upfront on an asset that might get tangled in export controls before Phase 3.

China's biotech sector isn't going to vanish. The talent pool of returning scientists, the massive patient population for clinical trials, and the sheer speed of execution in hubs like Shanghai's Zhangjiang Hi-Tech Park remain unmatched in Asia. Big Pharma still needs those drugs to survive its upcoming patent cliffs.

The era of frictionless, check-writing cross-border biotech deals is over. Every licensing agreement and venture term sheet now comes with a national security lawyer sitting at the table, and the firms that survive will be the ones that build clean, compliant corporate structures before Washington writes the next round of rules.

LZ

Lucas Zhang

A trusted voice in digital journalism, Lucas Zhang blends analytical rigor with an engaging narrative style to bring important stories to life.